---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-045401"
form_type: "8-K"
ticker: "IONS"
cik: "0000874015"
company_name: "IONIS PHARMACEUTICALS INC"
filed_at: "2023-09-27T23:59:59+00:00"
generated_at: "2026-06-10T08:27:14.381092+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ionis signs $60M upfront deal with Roche for two RNA programs for Alzheimer's and Huntington's

## Summary
- Ionis receives $60M upfront; Roche gains exclusive worldwide rights to develop and commercialize two undisclosed RNA-targeting medicines.
- Ionis responsible for pre-clinical advancement; Roche leads clinical development, manufacturing, and commercialization.
- Ionis eligible for development, regulatory, and commercial milestone payments plus tiered royalties.
- Programs target Alzheimer's disease and Huntington's disease; expands 10-year partnership including tominersen for HD.

## SEC filing metadata
- accession: 0001140361-23-045401
- form_type: 8-K
- ticker: IONS
- cik: 0000874015
- company_name: IONIS PHARMACEUTICALS INC
- filed_at: 2023-09-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874015/000114036123045401/0001140361-23-045401-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874015/000114036123045401/ef20011349_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-045401
- JSON: https://secwatch.observer/filing/0001140361-23-045401.json
- Plain text: https://secwatch.observer/filing/0001140361-23-045401.txt

## Key facts
- Material Agreements
  IONIS PHARMACEUTICALS INC entered into a collaboration with Roche (effective 2023-09-27).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Roche
  - Effective: 2023-09-27
  source text: On September 27, 2023, Ionis Pharmaceuticals, Inc. issued a press release announcing it has entered into an agreement with Roche for two early-stage programs for RNA-targeting investigational medicines for the treatment of Alzheimer’s disease and Huntington’s disease.
  evidence_url: https://www.sec.gov/Archives/edgar/data/874015/000114036123045401/0001140361-23-045401-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.